Legato Capital Management LLC Boosts Stock Holdings in Glaukos Co. (NYSE:GKOS)

Legato Capital Management LLC grew its position in Glaukos Co. (NYSE:GKOS - Free Report) by 85.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 9,381 shares of the medical instruments supplier's stock after acquiring an additional 4,309 shares during the period. Legato Capital Management LLC's holdings in Glaukos were worth $1,407,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of GKOS. Values First Advisors Inc. acquired a new stake in Glaukos during the 3rd quarter worth about $25,000. Harvest Fund Management Co. Ltd lifted its position in Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier's stock valued at $117,000 after acquiring an additional 860 shares in the last quarter. KBC Group NV lifted its position in Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier's stock valued at $188,000 after acquiring an additional 201 shares in the last quarter. EWA LLC bought a new position in shares of Glaukos during the 3rd quarter worth approximately $209,000. Finally, Procyon Advisors LLC bought a new position in shares of Glaukos during the 3rd quarter worth approximately $210,000. 99.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on GKOS. JPMorgan Chase & Co. lifted their target price on shares of Glaukos from $130.00 to $145.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Truist Financial lifted their price objective on shares of Glaukos from $152.00 to $185.00 and gave the company a "buy" rating in a research note on Wednesday, December 18th. BTIG Research boosted their price target on shares of Glaukos from $140.00 to $149.00 and gave the company a "buy" rating in a research report on Tuesday, November 26th. Piper Sandler restated an "overweight" rating and set a $180.00 price target (up from $140.00) on shares of Glaukos in a research report on Monday, January 27th. Finally, Morgan Stanley lowered shares of Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 price target for the company. in a research report on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $151.08.

Insider Activity

In other Glaukos news, COO Joseph E. Gilliam sold 3,328 shares of the company's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $149.85, for a total value of $498,700.80. Following the sale, the chief operating officer now owns 102,169 shares in the company, valued at approximately $15,310,024.65. This represents a 3.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gilbert H. Kliman sold 2,000 shares of the company's stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total transaction of $288,020.00. Following the completion of the sale, the director now owns 32,336 shares in the company, valued at approximately $4,656,707.36. This trade represents a 5.82 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 15,328 shares of company stock valued at $2,289,521. Insiders own 6.40% of the company's stock.

Glaukos Stock Up 4.6 %

Glaukos stock traded up $6.68 during mid-day trading on Friday, hitting $153.06. The company's stock had a trading volume of 747,257 shares, compared to its average volume of 495,754. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The business has a 50 day moving average price of $151.66 and a 200-day moving average price of $138.22. Glaukos Co. has a 12 month low of $83.90 and a 12 month high of $163.71.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.